A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction.

Ping AnGuangyan WeiPinzhu HuangWenda LiXiaolong QiYi LinKahini A VaidJun WangShucha ZhangYang LiYat Sun OrLi-Juan JiangYury V Popov

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

EDP-305 potently improved pre-established liver injury and hepatic fibrosis in murine biliary and metabolic models of liver disease, supporting the clinical evaluation of EDP-305 in fibrotic liver diseases including cholangiopathies and non-alcoholic steatohepatitis.

Keyphrases

liver injury
drug induced
liver fibrosis
signaling pathway
idiopathic pulmonary fibrosis